A Phase I Study of Intrathecal Rituximab in Patients With Lymphomatous Meningitis

Lymphoma, B Cell Clinical Trial

Official title:
A Phase I Study of Intrathecal Rituximab in Patients With Lymphomatous Meningitis

Status Withdrawn

Clinical Trial Summary

The purpose of this study is to define the safety profile of rituximab given intrathecally in lymphomatous meningitis related to CD20+ non-Hodgkin's lymphomas.

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00210340
Study type	Interventional
Source	International Extranodal Lymphoma Study Group (IELSG)
Contact
Status	Withdrawn
Phase	Phase 1

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00210379` - Phase II Study of Combined Modality Treatment in Primary Testicular Non-Hodgkin's Lymphoma	Phase 2
Terminated	`NCT00523939` - DepoCyt for Active Lymphomatous or Leukemic Meningitis	Phase 2
Completed	`NCT02679196` - The Safety, Pharmacokinetic and Pharmacodynamic Effect of KA2237 (PI3 Kinase p110β/δ Inhibitor) In B Cell Lymphoma	Phase 1
Completed	`NCT00210314` - Phase II Trial of Combined Modality Treatment in Primary Central Nervous System Lymphoma	Phase 2
Not yet recruiting	`NCT02992834` - Anti-CD19:TCRζ Chimeric Antigen Receptor-T Cells in the Treatment for CD19+ B Cell Lymphoma	Phase 4